scholarly journals Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Yang Chen ◽  
YanRong Wang ◽  
Yan Shi ◽  
GuangHai Dai
Keyword(s):  
Colon Cancer ◽  
Retrospective Study ◽  
Cancer Patients ◽  
Metastatic Colon Cancer ◽  
Chemotherapy Induced Neutropenia

scholarly journals Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients

2016 ◽  
Vol 22 (6) ◽  
pp. 628-639 ◽  
Author(s):  
Andinet Woldemichael ◽  
Eberechukwu Onukwugha ◽  
Brian Seal ◽  
Nader Hanna ◽  
C. Daniel Mullins
Keyword(s):  
Colon Cancer ◽  
Cost Effectiveness ◽  
Cancer Patients ◽  
Metastatic Colon Cancer ◽  
The Cost

scholarly journals he effects of NETosis on fibrinolysis in colon cancer patients

2022 ◽  
Vol 20 (4) ◽  
pp. 25-31
Author(s):  
A. A. Parshina ◽  
N. N. Tsybikov ◽  
P. P. Tereshkov ◽  
T. M. Karavaeva ◽  
M. V. Maksimenya
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Cell Activation ◽  
Fluorescent Microscopy ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Metastatic Colon Cancer ◽  
The Given ◽  
Experimental Group ◽  
Pai 1

Aim. To investigate formation of neutrophil extracellular traps (NETs) and their impact on fibrinolysis in patients with colon cancer.Materials and methods. The study was performed in two groups. The experimental group consisted of patients with stage 2–3 non-metastatic colon cancer (n = 17, average age – 67 years). The control group included healthy volunteers matched by sex and age (n = 30, average age – 68 years). An experimental model was created from the whole blood. It included platelet-poor plasma and an isolated culture of neutrophils, previously induced to NETosis by adding 100 nmol PMA. The samples were incubated for 4 hours, then the test tubes were centrifuged to pellet cells and their remnants, and the plasma was transferred for subsequent examination. The plasma incubated with intact neutrophils was used as a control. The levels of interleukin-8 (IL-8) and P-selectin glycoprotein ligand-1 (PSGL-1) were used to determine the degree of cell activation. NETosis was confirmed by enzyme-linked immunosorbent assay (ELISA) and fluorescent microscopy. Fibrinolysis was assessed using the thrombodynamics test. The results were compared with the levels of fibrinolytic system components measured by flow cytometry.Results. In the control group, NETosis induction contributed to pronounced neutrophil activation that was accompanied by an increase in the IL-8, PSGL-1, and plasminogen levels, a decrease in PAI-1, and enhancement of fibrinolysis, compared with the intact samples. Higher levels of IL-8, PSGL-1, plasminogen, and PAI-1 and intensified fibrinolysis were detected in the intact samples. However, PMA-induced NETosis did not result in an increase in the degree of activation and significant changes in the given parameters.Conclusion. NETosis promotes both formation and lysis of fibrin clots. However, in cancer patients, suicidal NETosis does not contribute to fibrinolysis due to intracellular protease depletion, which may be one of the mechanisms causing hypercoagulation and insufficient fibrinolysis in cancer. 

VEGFR2 expressions in Th1 and CD8+ cytotoxic T lymphocytes (CTL) in colon cancer patients.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15535-e15535
Author(s):  
Mehmet Artac ◽  
Ayca Ceylan ◽  
Melek Karakurt Eryılmaz ◽  
Murat Araz ◽  
Mustafa Karaagac ◽  
...  
Keyword(s):  
Colon Cancer ◽  
T Cell ◽  
Cancer Patients ◽  
Study Groups ◽  
T Cell Subsets ◽  
Control Group ◽  
Study Group ◽  
Metastatic Colon Cancer ◽  
Vegf Receptors ◽  
Cancer History

e15535 Background: VEGF receptors have an important role for inhibiting adaptive immun response in colon cancer. Therefore, we analyzed VEGF receptors in circulating T cell subsets according to stage in colon cancer patients. Methods: The prospective study group consisted of 50 patients with histologically confirmed colon cancer and 30 person without any cancer history as a control group. Peripheral blood specimens were collected from the patients after the diagnosis before inducing chemotherapy and radiotherapy. Patients with active infections or autoimmune disorders, who were treated with steroids and antibiotics in the last four weeks before the study enrollment were excluded from the study group. VEGFR2 expressions in circulating T cell subsets (Th1, Th2, Th17, CTL) were analyzed by flow cyctometry. Results: Age and gender were not different between the all study groups. Mean circulating CD4+ folicullar cells were less in colon cancer patients (9.54%±3.99) than the control group (12.03%±4.34), (p < 0.01). Mean circulating CD8+ follicular cells were higher in metastatic colon cancer (n = 26) 2.48% ± 1.68, than the non-metastatic colon cancer patients (n = 24) 1.63% ± 1.37, (p = 0.02). Mean VEGFR2 expressions in Th1 cells were higher in colon cancer patients 248.8 (Mean Flourescein intensity-MFI) than the control group 224.6, (P = 0.006). Mean VEGFR2 expressions in CTL were higher in colon cancer patients (381.8) than the control group (284.7), (p < 0.001). PD-1 expressions were not different between the colon cancer patients and the control group in all circulating T cell subsets. Mean VEGFR2 expressions in Th17 cells were higher non-metastatic colon cancer patients than the metastatic colon cancer patients (326.5 and 268.4 MFI, respectively, p = 0.02). Conclusions: VEGFR2 expressions are increased in circulating Th1 and CTL subsets in colon cancer patients. Whereas PD-1 expressions were not different in circulating T cell subsets than the control. VEGFRs may play an important role for the inhibition of circulating T cell subsets in colon cancer.

scholarly journals Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab

2018 ◽  
Vol 29 ◽  
pp. v97
Author(s):  
V. Pacheco-Barcia ◽  
R. Mondéjar Solís ◽  
O. Martínez Saez ◽  
F. Longo Muñoz ◽  
E. Bermejo ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Emergency Surgery ◽  
Colonic Obstruction ◽  
Metal Stents ◽  
Metastatic Colon Cancer

Association of immune-regulatory (FoxP3+)-T-cell tumor infiltration status with benefit from chemoimmunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 3045-3045
Author(s):  
P. Correale ◽  
P. Tagliaferri ◽  
M. T. Del Vecchio ◽  
C. Remondo ◽  
C. Migali ◽  
...  
Keyword(s):  
Colon Cancer ◽  
T Cells ◽  
Cancer Patients ◽  
Cox Regression ◽  
Treg Cells ◽  
Phase Iii ◽  
Metastatic Colon Cancer ◽  
Tumor Infiltration ◽  
Gm Csf ◽  
Independent Variable

3045 Background: GOLFIG is a novel chemoimmunotherapy regimen, combining gemcitabine, oxaliplatin, 5-FU/FA with immunoadjuvant GM-CSF and aldesleukine, which resulted safe and very active in colon cancer patients. Antitumor activity and immunity feedback to the treatment resulted strictly correlated. The best outcome was observed in patients showing autoimmunity signs, rise in central-memory-T cells, and decline in peripheral and tumor infiltrating immuno-regulatory T (Treg) cells. On these bases, we investigated a possible correlation between Treg tumor infiltration at diagnosis and clinical outcome of these patients. Methods: An immunohistochemistry study was carried out to quantify the infiltration of Treg (FoxP3+) lymphocytes in tumor samples of 41 colon cancer patients who received FOLFOX-4 chemotherapy or GOLFIG chemo-immunotherapy as enrolled in the ongoing phase III GOLFIG-2 trial. Treg tumor infiltration score (range 0 to 5) was then correlated with survival (OS) and time to progression (TTP). Results: A higher Treg tumor infiltration score (score 3–5) was associated to a longer OS and TTP in the whole patient population (high vs low score; TTP=18 vs 9.4 months; p=0.002; OS=55.7 vs 28.9 months; p=0.001); however, those patients with high tumor infiltration of FoxP3+-T cells who received GOLFIG regimen showed the most favorable outcome (high vs low score; TTP=20.8 vs 11.6 months; p=0.04; OS=68.1 vs 41 months; p=0.04). A Cox regression model demonstrated in these patients that a high Treg tumor infiltration score is an independent variable of long survival and prolonged TTP. Conclusions: Our results suggest that GOLFIG chemoimmunotherapy is highly effective in colon carcinoma patients with high FoxP3+ infiltration score and that Treg-tumor infiltration score may be a favorable prognostic marker in colon cancer patients. No significant financial relationships to disclose.

Outcome of colon cancer patients with synchronous metastases

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4029-4029
Author(s):  
I. Sobhani ◽  
F. Roudot-Thoraval ◽  
F. Mesli ◽  
B. Landi ◽  
T. Aparicio ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Cox Model ◽  
Univariate Analysis ◽  
Colon Surgery ◽  
Teaching Hospitals ◽  
Rank Test ◽  
Metastatic Colon Cancer ◽  
Curative Surgery ◽  
Synchronous Metastases

4029 Background: Metastatic colon cancer patients may undergo chemotherapy without colon surgery. However, the outcome of patients has not been evaluated and antiagiogenic agents can not be given. The aim of the present cohort study was to analyse factors influencing patients’ survival. Methods: Consecutive patients [N=228, mean age (sd) 64 (12) yrs, median follow-up 20 mths;84 females] treated in 6 teaching hospitals received chemotherapy for metastatic colonic cancer, either as the first step, or after surgery. Progressive free survival (PFS) was estimated using Kaplan-Meïer method. Factors associated with PFS were tested by means of Log rank test and results are presented in terms of medians of survival (95% CI). Factors independently related to PFS were tested using a Cox model and results are presented as hazard ratio. Results: 105 patients with colon cancer and synchronous metastatsis underwent colon surgery prior to chemotherapy (68 males, mean age 64 yrs) when 123 patients were treated first by chemotherapy ± biotherapy (76 males, mean age 63 yrs). By univariate analysis, following factors were significantly associated with PFS: surgery first 25.5 (18.6 - 32.5) vs chemotherapy first 18.3 (14.7 - 21.9) mths p = 0.006; curative surgery: yes 35.7 (29.6 - 41.8) vs no 18.4 (15.6 - 21.2) mths p < 0.001; tumour histological differentiation : no : 13.4 (6.2 - 20.6) vs well : 24.7 (20.4 - 29.1) mths p<0.001; synchronous metastases: liver only 25.5 (20.5 - 30.6) vs peritonea&nodes : 18.4 (10.6 - 26.1) vs pulmonary & other sites : 16.5 (14.7 - 18.3) mths p < 0.0001; need for colonic stent: yes 16.4 (9.3 - 23.5) vs no 23.9 (21.1 - 26.7) months p < 0.0001; antiangiogenic drug: yes 36.6 (28.7 - 44.5) vs no : 20.7 (18.3 - 23.1) p = 0.033. After Cox multivariate analysis five independent factors were found to be associated with PFS. Conclusions: Colon surgery before chemotherapy plus bevacizumab appears to be the more appropriate choice, and associated with longer PFS, especially for those patients with well differentiated tumours and synchronous liver metastases. [Table: see text] No significant financial relationships to disclose.

Fatigue control in metastatic colon cancer treated with capecitabine and oxaliplatin.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e19628-e19628
Author(s):  
Fernanda Maris Peria ◽  
Lilian Andrade Sá ◽  
Harley Francisco Oliveira ◽  
Josiane Cheli Vettori ◽  
Daniela Pretti da Cunha Tirapelli ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colon Cancer ◽  
Cancer Patients ◽  
Palliative Chemotherapy ◽  
Large Population ◽  
Concurrent Chemotherapy ◽  
Metastatic Colon Cancer ◽  
Chemotherapy Treatment ◽  
Chi Squared

e19628 Background: Fatigue is one of the most frequent symptoms in cancer patients, characterized by profound fatigue that is not relieved by rest. This symptom can be identified at the time of diagnosis and could affects up to 90% of patients undergoing cancer treatment. There are some instruments available in the literature that can characterize the presence of fatigue through clinical questioning. Methods: Considering the large population of patients with metastatic colorectal cancer treated with chemotherapy and the prevalence of fatigue in these patients, this study evaluated the presence of fatigue in 27 metastatic colon cancer patients before the first, second, third and fourth cycles of fist line palliative chemotherapy regimen containing CAPOX (capecitabine and oxaliplatin) by applying the evaluation questionnaire FACIT-F fatigue. Results: The results post Friedman chi-squared test demonstrated that there was no improvement of fatigue during these four cycles of CAPOX palliative chemotherapy (p=0,2574). The FACIT-G analysis demonstrated no worsening of quality of life (p=0,2411) during and between the four cycles of chemo. All different parameters included in FACIT-F questionnaires: emotional (p=0,2629), physical (p=0,3199), familiar (p=0,1456), functional (p=0,8662) and specific fatigue topic (p=0,7569) confirmed no difference between the cycles. Conclusions: Despite the metastatic stage of colon cancer patients and concurrent chemotherapy treatment, there was no fatigue improvement during the four first CAPOX chemo cycles courses and there was the maintenance of quality of life.

Sign in / Sign up

Export Citation Format

Share Document